


First granted ICOone® patent in China
The Chinese Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device ICOone.
Iconovo…

Iconovo Q3-2021 quarterly report
New nasal inhaler has great potential in treatment of COVID-19
Key figures in TSEK unless otherwise indicated
Jul-Sep 2021
Jul-Sep 2020
Jan-Sep…

Meet Iconovo at Bio-Europe Digital
Iconovo will participate at Bio-Europe Digital, an online event that will be held 25-28 October. Here we will present ICOone - our disposable single-dose…

Iconovo develops inhaled Covid-19 vaccine
BBC, and a line of other media channels, has acknowledged Iconovo and its groundbreaking work with immunotherapy company ISR for the development of inhaled…

Iconovo will participate at CPhI Milan
Iconovo will participate at the CPhI event in Milan Italy, 9-11 November 2021. Here thousands of pharma suppliers and buyers unite, connect and do business.…

ICOpre – the story behind a new, generic inhaler platform to Ellipta
Iconovo has developed a new and innovative dry powder inhaler platform - ICOpre - aimed for a global market. ICOpre is a pre-metered dry powder inhaler…

Iconovo looks to the US where it now meets quality requirements
Biostock published September 24th an article about Iconovo that can be found in its entirety below
One of Iconovo’s goals is to launch future inhalation…

Iconovo meets US Quality System regulation for medical devices
Iconovo AB (publ), that develops complete inhalation products for a global market today annonces that the company´s Quality Management System…

CEO Johan Wäborg, Pareto Securities´12th Annual Healthcare Conference September 2021
Pareto Securities´12th Annual Healthcare Conference
CEO Johan Wäborg presents Iconovo.

Iconovo’s partner explores opportunities in Bangladesh
Biostock published August 27th an article about Iconovo that can be found in its entirety below
Together with ISR, Iconovo is developing an inhaled…

Second ICOres® patent granted in Japan
Japan Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device, ICOres. Iconovo…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se